# Tandem Diabetes Care Inc. (TNDM)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.06B  
**Price:** $15.81 (-2.59%)

> Tandem Diabetes Care designs, develops, and commercializes advanced technology solutions for insulin-dependent diabetes management worldwide. The company's flagship products are the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology that helps optimize blood glucose levels. These durable insulin pumps work alongside continuous glucose monitoring systems, including integration with Abbott's FreeStyle Libre 3 Plus sensor. Tandem also manufactures disposable products such as infusion sets and cartridges for insulin storage and delivery. Nearly three-quarters of revenue derives from the United States, with the remainder primarily from other developed nations. The company serves individual patients with insulin-dependent diabetes across multiple distribution channels, including direct sales, pharmacy partnerships, and healthcare providers. Founded in 2006 and headquartered in San Diego, California, Tandem operates as a global leader in automated insulin delivery technology.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.01B | $546M | -$187M | -$205M | $-3.04 |
| 2024 | $940M | $490M | -$99M | -$96M | $-1.47 |
| 2023 | $748M | $368M | -$233M | -$223M | $-3.43 |
| 2022 | $801M | $413M | -$93M | -$95M | $-1.47 |
| 2021 | $703M | $376M | $23M | $16M | $0.24 |
| 2020 | $499M | $261M | -$8M | -$34M | $-0.56 |
| 2019 | $362M | $194M | -$17M | -$25M | $-0.42 |
| 2018 | $184M | $90M | -$45M | -$123M | — |
| 2017 | $108M | $44M | -$63M | -$73M | — |
| 2016 | $84M | $24M | -$78M | -$83M | — |
| 2015 | $73M | $27M | -$69M | -$72M | — |
| 2014 | $50M | $15M | -$76M | -$80M | — |
| 2013 | $29M | $6M | -$49M | -$63M | — |
| 2012 | $2M | -$1M | -$33M | -$33M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $881M | $726M | $155M | $91M | $310M |
| 2024 | $968M | $705M | $263M | $69M | $308M |
| 2023 | $953M | $639M | $314M | $59M | $285M |
| 2022 | $1.05B | $613M | $440M | $173M | — |
| 2021 | $905M | $472M | $433M | $71M | — |
| 2020 | $716M | $350M | $366M | $95M | — |
| 2019 | $326M | $131M | $195M | $51M | — |
| 2018 | $206M | $75M | $131M | $42M | — |
| 2017 | $95M | $124M | -$29M | $14M | $83M |
| 2016 | $112M | $118M | -$6M | $45M | $81M |
| 2015 | $125M | $61M | $63M | $43M | $30M |
| 2014 | $106M | $52M | $55M | $31M | $30M |
| 2013 | $162M | $47M | $116M | $124M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$10M | $20M | -$30M |
| 2024 | $24M | $19M | $5M |
| 2023 | -$32M | $27M | -$59M |
| 2022 | $50M | $34M | $16M |
| 2021 | $111M | $14M | $97M |
| 2020 | $25M | $27M | -$3M |
| 2019 | $42M | $20M | $22M |
| 2018 | -$8M | $3M | -$11M |
| 2017 | -$66M | $6M | -$72M |
| 2016 | -$61M | $9M | -$70M |

Source: [CompaniesByCap](https://companiesbycap.com/company/TNDM)